LU92899I2 - Gardasil-9/vaccination contre les stéréotypes 16,18 et 31 nom de produit: hpv l1 vlps 16+18+31 - Google Patents

Gardasil-9/vaccination contre les stéréotypes 16,18 et 31 nom de produit: hpv l1 vlps 16+18+31 Download PDF

Info

Publication number
LU92899I2
LU92899I2 LU92899C LU92899C LU92899I2 LU 92899 I2 LU92899 I2 LU 92899I2 LU 92899 C LU92899 C LU 92899C LU 92899 C LU92899 C LU 92899C LU 92899 I2 LU92899 I2 LU 92899I2
Authority
LU
Luxembourg
Prior art keywords
gardasil
stereotypes
vlps
hpv
product name
Prior art date
Application number
LU92899C
Other languages
English (en)
French (fr)
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0413510.9A external-priority patent/GB0413510D0/en
Priority claimed from US11/114,301 external-priority patent/US20050287161A1/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of LU92899I2 publication Critical patent/LU92899I2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
LU92899C 2004-06-16 2015-12-08 Gardasil-9/vaccination contre les stéréotypes 16,18 et 31 nom de produit: hpv l1 vlps 16+18+31 LU92899I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0413510.9A GB0413510D0 (en) 2004-06-16 2004-06-16 Vaccine
US11/114,301 US20050287161A1 (en) 2002-12-20 2005-04-26 Vaccine
PCT/EP2005/006461 WO2005123125A1 (en) 2004-06-16 2005-06-14 Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52

Publications (1)

Publication Number Publication Date
LU92899I2 true LU92899I2 (fr) 2016-03-08

Family

ID=35160037

Family Applications (3)

Application Number Title Priority Date Filing Date
LU92899C LU92899I2 (fr) 2004-06-16 2015-12-08 Gardasil-9/vaccination contre les stéréotypes 16,18 et 31 nom de produit: hpv l1 vlps 16+18+31
LU92900C LU92900I2 (fr) 2004-06-16 2015-12-08 Gardasil-9/vaccination contre les stéréotypes 16,18 et 31 nom de produit: hpv l1 vlps 16+18+31
LU92898C LU92898I2 (fr) 2004-06-16 2015-12-08 Gardasil-9/vaccination contre les stéréotypes 16,18 et 31 nom de produit: hpv l1 vlps 16+18+31

Family Applications After (2)

Application Number Title Priority Date Filing Date
LU92900C LU92900I2 (fr) 2004-06-16 2015-12-08 Gardasil-9/vaccination contre les stéréotypes 16,18 et 31 nom de produit: hpv l1 vlps 16+18+31
LU92898C LU92898I2 (fr) 2004-06-16 2015-12-08 Gardasil-9/vaccination contre les stéréotypes 16,18 et 31 nom de produit: hpv l1 vlps 16+18+31

Country Status (18)

Country Link
EP (1) EP1758609B1 (enExample)
JP (1) JP2008502633A (enExample)
KR (1) KR20070029254A (enExample)
AR (1) AR049354A1 (enExample)
AU (1) AU2005253723B2 (enExample)
BR (1) BRPI0512042B8 (enExample)
CA (1) CA2566620C (enExample)
FR (2) FR15C0082I2 (enExample)
IL (1) IL179138A0 (enExample)
LU (3) LU92899I2 (enExample)
MA (1) MA28692B1 (enExample)
MX (1) MXPA06014515A (enExample)
NO (1) NO20070195L (enExample)
PE (1) PE20060434A1 (enExample)
PL (1) PL1758609T3 (enExample)
RU (1) RU2420313C2 (enExample)
SG (1) SG153837A1 (enExample)
WO (1) WO2005123125A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007013475A (es) * 2005-04-26 2008-04-02 Glaxosmithkline Biolog Sa Vacuna.
ES2519490T3 (es) * 2008-07-31 2014-11-07 Glaxosmithkline Biologicals S.A. Vacuna contra HPV
US9566323B2 (en) * 2009-06-19 2017-02-14 Eyegene Inc. Vaccine for cervical cancer
CN103119168A (zh) * 2010-07-15 2013-05-22 不列颠哥伦比亚癌症局分支机构 人乳头瘤病毒e7抗原组合物及其用途
EP3269388A1 (en) 2012-10-30 2018-01-17 Pfizer Inc. Recombinant particle based vaccines against human cytomegalovirus infection
CA2965498A1 (en) * 2014-10-24 2016-04-28 Hpvvax, Llc. Compositions and uses of a papilloma virus (hpv) vaccine for the treatment of hpv related cancer and skin lesions
CN107188966B (zh) 2016-03-15 2020-03-31 中国医学科学院基础医学研究所 一种乳头瘤病毒嵌合蛋白及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
PT1572233E (pt) * 2002-12-20 2011-06-07 Glaxosmithkline Biolog Sa Utilização de hpv16 e hpv18 como vacina contra um ou mais de tipos de hpv oncogénicos 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68

Also Published As

Publication number Publication date
RU2006143804A (ru) 2008-08-20
AR049354A1 (es) 2006-07-19
CA2566620A1 (en) 2005-12-29
WO2005123125A1 (en) 2005-12-29
CA2566620C (en) 2014-03-11
MXPA06014515A (es) 2007-03-23
FR15C0082I2 (fr) 2016-10-28
EP1758609A1 (en) 2007-03-07
AU2005253723B2 (en) 2011-01-20
LU92900I2 (fr) 2016-03-08
BRPI0512042A (pt) 2008-02-06
PE20060434A1 (es) 2006-06-08
AU2005253723A1 (en) 2005-12-29
KR20070029254A (ko) 2007-03-13
JP2008502633A (ja) 2008-01-31
BRPI0512042B1 (pt) 2019-01-22
LU92898I2 (fr) 2016-03-08
RU2420313C2 (ru) 2011-06-10
IL179138A0 (en) 2007-03-08
FR15C0082I1 (fr) 2016-01-08
EP1758609B1 (en) 2012-10-03
PL1758609T3 (pl) 2013-02-28
FR15C0084I1 (enExample) 2016-01-08
SG153837A1 (en) 2009-07-29
FR15C0084I2 (fr) 2016-10-28
NO20070195L (no) 2007-01-15
MA28692B1 (fr) 2007-06-01
BRPI0512042B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
LU92898I2 (fr) Gardasil-9/vaccination contre les stéréotypes 16,18 et 31 nom de produit: hpv l1 vlps 16+18+31
NO2017005I1 (no) Human pappilomavirus vaksine [type 6, 11, 16, 18, 31, 33, 45, 52, 58]
EP2262883A4 (en) CLEANING, DISINFECTING AND STERILIZING PREPARATIONS
LU92902I2 (fr) Gardasil-9/nom du produit: protéine hpv 45 l1
GB0425569D0 (en) Biological products
LU92901I2 (fr) Gardasil-9/ nom du produit: protéine hpv58l1
EP2046352A4 (en) Fermented milk product and use thereof
IL182470A0 (en) Semi-soft c-class immunostimulatory oligonucleotides
PL2094849T3 (pl) Długotrwała zmiana przebiegu choroby z zastosowaniem oligonukleotydów immunostymulujących
EP1724120A4 (en) HYDRAULIC TRANSFER PRODUCT
EP2167083A4 (en) NOVEL HETEROARYL-3-AZABICYCLOÝ3.1.0HEXANES, THEIR METHODS OF PREPARATION AND THEIR USE AS MEDICAMENTS
ITTO20040434A1 (it) Confezione multipla di buste contenenti prodotti ad uso medicale.
EP1933989A4 (en) PERFUME PRODUCT, DONOR AND DONOR ASSEMBLY
GB0520169D0 (en) Biological products
ATE405326T1 (de) Kosmetiktuchprodukt
GB2411205B (en) Disposable products
GB0506912D0 (en) Biological products
ITTO20060175U1 (it) Espositore, particolarmente adatto per prodotti dolciari.
FI20031065A0 (fi) Hyönteissuoja-aine, menetelmä sen valmistamiseksi ja sen käyttö
FR2859212B1 (fr) Fluxant, solumere et composition bitumineuse en contenant, preparation et application de ces produits
ITFI20080009A1 (it) "confezione per prodotti in carta tissue, per carta igienica od altro"
PL1889595T3 (pl) Wyrób do oczyszczania i/lub pielęgnacji skóry oraz sposób wytwarzania wspomnianego wyrobu
ITRM20040509A1 (it) Procedimento di ingobbio per caramiche e prodotto derivato.
AU2005902986A0 (en) Single-use container, closure and serving implement
ITBG20040037A1 (it) Prodotto dolciario